167 related articles for article (PubMed ID: 33617305)
1. Understanding Treatment Strategies and Preferences in Nonmetastatic Castration-Resistant Prostate Cancer From the Japanese Physician Perspective.
Suzuki K; Grillo V; Chen Y; Singh S; Ledesma DA
JCO Glob Oncol; 2021 Feb; 7():302-310. PubMed ID: 33617305
[TBL] [Abstract][Full Text] [Related]
2. Unmet needs in non-metastatic castration-resistant prostate cancer from the Japanese patient perspective: a discrete choice experiment.
Uemura H; Matsushima H; Yokomizo A; Kobayashi K; Arai G; Satoh T; Grillo V; Chen Y; Singh S; Ledesma DA
BMJ Open; 2021 Aug; 11(8):e052471. PubMed ID: 34400460
[TBL] [Abstract][Full Text] [Related]
3. Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment.
Uemura H; Matsubara N; Kimura G; Yamaguchi A; Ledesma DA; DiBonaventura M; Mohamed AF; Basurto E; McKinnon I; Wang E; Concialdi K; Narimatsu A; Aitoku Y
BMC Urol; 2016 Nov; 16(1):63. PubMed ID: 27814714
[TBL] [Abstract][Full Text] [Related]
4. Physician preferences for non-metastatic castration-resistant prostate cancer treatment.
Srinivas S; Mohamed AF; Appukkuttan S; Botteman M; Ng X; Joshi N; Horodniceanu E; Waldeck AR; Simmons SJ
BMC Urol; 2020 Jun; 20(1):73. PubMed ID: 32571276
[TBL] [Abstract][Full Text] [Related]
5. Patients' preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation.
Rentz AM; Mansukhani SG; Liu J; Lloyd AJ; Heidenreich S; Matza LS; Dawson NA; Shore N; Freedland SJ
Urol Oncol; 2021 Jun; 39(6):367.e7-367.e17. PubMed ID: 33736976
[TBL] [Abstract][Full Text] [Related]
6. Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment.
Srinivas S; Mohamed AF; Appukkuttan S; Botteman M; Ng X; Joshi N; Tsai JH; Fang J; Waldeck AR; Simmons SJ
Cancer Med; 2020 Sep; 9(18):6586-6596. PubMed ID: 32725755
[TBL] [Abstract][Full Text] [Related]
7. Physician preferences for nonmetastatic castration-resistant prostate cancer treatment in China.
Fan Y; Guo X; Campobasso D; He Z
Front Oncol; 2024; 14():1382678. PubMed ID: 38835395
[TBL] [Abstract][Full Text] [Related]
8. Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey.
George DJ; Mohamed AF; Tsai JH; Karimi M; Ning N; Jayade S; Botteman M
Cancer Med; 2023 Mar; 12(5):6040-6055. PubMed ID: 36226867
[TBL] [Abstract][Full Text] [Related]
9. Physicians' preferences for bone metastases treatments in France, Germany and the United Kingdom.
Qian Y; Arellano J; Gatta F; Hechmati G; Hauber AB; Mohamed AF; Bahl A; von Moos R; Body JJ
BMC Health Serv Res; 2018 Jul; 18(1):518. PubMed ID: 29970078
[TBL] [Abstract][Full Text] [Related]
10. Patients' Preferences for the Treatment of Metastatic Castrate-resistant Prostate Cancer: A Discrete Choice Experiment.
Eliasson L; de Freitas HM; Dearden L; Calimlim B; Lloyd AJ
Clin Ther; 2017 Apr; 39(4):723-737. PubMed ID: 28366592
[TBL] [Abstract][Full Text] [Related]
11. Relative importance of clinical outcomes and safety risks of antiseizure medication monotherapy for patients and physicians: Discrete choice experiment eliciting preferences in real-world study "VOTE".
Rosenow F; Winter Y; Leunikava I; Brunnert M; Joeres L; Sutphin J; Boeri M; Smith J; Villani F; Brandt C
Epilepsia; 2022 Feb; 63(2):451-462. PubMed ID: 34921391
[TBL] [Abstract][Full Text] [Related]
12. Does docetaxel prolong survival of patients with non-metastatic castration-resistant prostate cancer?
Ito K; Kimura T; Onuma H; Tabata R; Shimomura T; Miki K; Tomita M; Egawa S
Prostate; 2018 May; 78(7):498-505. PubMed ID: 29473179
[TBL] [Abstract][Full Text] [Related]
13. Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population.
Wu B; Li SS; Song J; Pericone CD; Behl AS; Dawson NA
J Med Econ; 2020 Jan; 23(1):54-63. PubMed ID: 31589086
[No Abstract] [Full Text] [Related]
14. Physicians' preferences for bone metastases drug therapy in the United States.
Arellano J; Hauber AB; Mohamed AF; Gonzalez JM; Collins H; Hechmati G; Gatta F; Qian Y
Value Health; 2015 Jan; 18(1):78-83. PubMed ID: 25595237
[TBL] [Abstract][Full Text] [Related]
15. Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in Japan.
Nakayama M; Kobayashi H; Okazaki M; Imanaka K; Yoshizawa K; Mahlich J
Am J Mens Health; 2018 Jul; 12(4):1094-1101. PubMed ID: 29774804
[TBL] [Abstract][Full Text] [Related]
16. Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer.
Mori K; Kimura T; Fukuokaya W; Iwatani K; Sakanaka K; Kurokawa G; Yanagisawa T; Sasaki H; Miki J; Shimomura T; Miki K; Hatano T; Endo K; Egawa S
Int J Clin Oncol; 2020 Mar; 25(3):479-485. PubMed ID: 31512007
[TBL] [Abstract][Full Text] [Related]
17. Patient Preferences for Metastatic Hormone-Sensitive Prostate Cancer Treatments: A Discrete Choice Experiment Among Men in Three European Countries.
de Freitas HM; Ito T; Hadi M; Al-Jassar G; Henry-Szatkowski M; Nafees B; Lloyd AJ
Adv Ther; 2019 Feb; 36(2):318-332. PubMed ID: 30617763
[TBL] [Abstract][Full Text] [Related]
18. Shared Decision-Making in Patients With Prostate Cancer in Japan: Patient Preferences Versus Physician Perceptions.
Schaede U; Mahlich J; Nakayama M; Kobayashi H; Takahashi Y; Saito K; Uemura H; Tokumitsu M; Yoshizawa K
J Glob Oncol; 2018 Sep; 4():1-9. PubMed ID: 30241183
[TBL] [Abstract][Full Text] [Related]
19. Treatment characteristics for nonmetastatic castration-resistant prostate cancer in the United States, Europe and Japan.
Shah R; Botteman M; Waldeck R
Future Oncol; 2019 Dec; 15(35):4069-4081. PubMed ID: 31687847
[No Abstract] [Full Text] [Related]
20. Conceptual assessment of HRQOL among Japanese non-metastatic castration-resistant prostate cancer (nmCRPC) patients.
Nishimura K; Shiota M; Eto M; Satoh T; Stroupe A; Seo C; Uzumcu A; Ledesma DA
Cancer Med; 2023 Jan; 12(2):1762-1778. PubMed ID: 35770744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]